Novo Nordisk's Keenly Awaited Semaglutide Trial To ‘Redefine’ Alzheimer’s?
Late-Stage EVOKE Set To Complete September 2025
Novo Nordisk has initiated its Phase III trial assessing its oral GLP-1 semaglutide in early Alzheimer’s disease patients. The firm’s veteran GLP-1 agonist pioneer Lotte Bjerre Knudsen explains its promise to Scrip.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: a preview of the ASCO meeting; small biopharma companies thrive in the US; the world’s first positive Phase III data for a microbiome therapy; Adaptimmune’s plans for its T-cell receptor therapy; and Novo looks at semaglutide in early Alzheimer’s.
Novo Nordisk at its Q1 update lifted full-year guidance and voiced confidence it can double sales of innovative treatments for obesity by 2025.
US CMO Todd Hobbs told Scrip the full launch will be in early 2020 as sales, manufacturing and reimbursement preparations for oral semaglutide continue based on the now-approved FDA label in type 2 diabetes.